639 patents
Page 4 of 32
Utility
1H-BENZO[D]IMIDAZOLE Derivatives As TLR9 Inhibitors for the Treatment of Fibrosis
21 Sep 23
David S. Yoon, Alicia Regueiro-Ren, Michael Mandler, Shoshana L. Posy, Chunjian Liu
Filed: 18 Aug 21
Utility
Methods of Treating Tumor
21 Sep 23
The disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer (SCLC) having a high tumor mutational burden (TMB) status comprising administering to the subject a monotherapy comprising an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody.
Prabhu Seshaiyer BHAGAVATHEESWARAN, Nicholas Allan John BOTWOOD, Han CHANG, William J. GEESE, Sabine MAIER, Giovanni SELVAGGI, Joseph Daniel SZUSTAKOWSKI
Filed: 17 Oct 22
Utility
Methods of Treating Autoimmune Disease Using a Domain Antibody Directed Against CD40L
21 Sep 23
Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, Pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided.
MAREK HONCZARENKO, VAISHALI SHAH, LIXIN LANG, URVI ARAS, DIANE SHEVELL, CHRISTINE KRATT, KAREN PRICE, SUZANNE SUCHARD
Filed: 21 Sep 22
Utility
AGONISTS OF ROR GAMMAt
21 Sep 23
The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
Lalgudi S. Harikrishnan, Brian E. Fink, Patrice Gill, Lan-Ying Qin, Muthoni G. Kamau, Tram N. Huynh, Ashok Vinayak Purandare, Honghe Wan, Daniel O’Malley
Filed: 8 May 20
Utility
Histone Demethylase Inhibitors
14 Sep 23
The present invention relates generally to compositions and methods for treating cancer and neoplastic disease.
Young K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
Filed: 24 Mar 23
Utility
Enhancing Anti-cancer Activity of Immunomodulatory FC
Fusion Proteins
14 Sep 23
The present disclosure provides a method for enhancing the anti-tumor efficacy of an Fc fusion protein which binds specifically to a target, e.g., a co-inhibitory or co-stimulatory receptor of ligand, on a T cell in a subject afflicted with a cancer or a disease caused by an infectious agent and alters the activity of the immunomodulatory target, thereby potentiating an endogenous immune response against cells of the cancer or the infectious agent, wherein the method comprises selecting, designing or modifying the Fc region of the Fc fusion protein so as to enhance the binding of said Fc region to an activating Fc receptor (FcR).
John J. ENGELHARDT, Alan J. KORMAN, Michael QUIGLEY, Mark J. SELBY, Changyu WANG
Filed: 27 Feb 23
Utility
Methods of Treating a Tumor Using an ANTI-PD-1 Antibody
7 Sep 23
This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity.
Robin EDWARDS, William J. GEESE, Danielle M. GREENAWALT
Filed: 30 Jan 23
Utility
METHODS OF USING CTLA4Ig SUBCUTANEOUS FORMULATIONS
7 Sep 23
The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous(SC) for treating immune system diseases and tolerance induction.
Manisha P Desai, Charles E. Dahlheim, Sunita Borsadia, Vijay H. Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
Filed: 3 Nov 22
Utility
Combination Therapy with ANTI-IL-8 Antibodies and ANTI-PD-1 Antibodies for Treating Cancer
7 Sep 23
Provided herein are methods for the clinical treatment of tumors (e.g., advanced solid tumors) in patients having certain levels of serum IL-8 using an anti-IL-8 antibody in combination with an anti-PD-1 antibody.
Michael CARLETON, David FELTQUATE, Olivier DE HENAU, Timothy Patrick REILLY, Tian CHEN, Ye FENG, Shu-Pang Ben HUANG, Ming ZHOU, Ramachandran SURESH
Filed: 29 Dec 22
Utility
Antibodies Against OX-40 and Uses Thereof
31 Aug 23
Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40.
Zhehong CAI, Indrani CHAKRABORTY, Marie-Michelle Navarro GARCIA, Thomas D. KEMPE, Alan J. KORMAN, Alexander T. KOZHICH, Hadia LEMAR, Mark MAURER, Christina Maria MILBURN, Michael QUIGLEY, Xiang SHAO, Mohan SRINIVASAN, Kent THUDIUM, Susan Chien-Szu WONG, Jochem GOKEMEIJER, Xi-Tao WANG, Han CHANG, Patrick GUIRNALDA
Filed: 11 Aug 22
Utility
Process for the Preparation of 6-(CYCLOPROPANEAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE
31 Aug 23
Ke Chen, Joerg Deerberg, Dong Lin, Michael Dummeldinger, Bahar Inankur, Sergei Kolotuchin, Jun Li, Amanda J. Rogers, Victor W. Rosso, Eric M. Simmons, Maxime C.D. Soumeillant, Daniel S. Treitler, Jianji Wang, Bin Zheng, Michael J. Smith, Neil A. Strotman, Steven Tymonko, Tamas Benkovics
Filed: 13 Apr 23
Utility
Extended Release Dosage Forms for TYK2 Inhibitors
17 Aug 23
Stable and bioavailable extended-release formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyrid azine-3-carboxamide (Formula (I); BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.
Sherif Ibrahim Farag Badawy, Jonathan R. Brown, Candice Y. Choi, Christoph Gesenberg, Vivienne Gary, John Wynne Jones, Umesh Kestur, Balvinder S. Vig, Xiaotian S. Yin, Christopher A. Zordan, Corey Bloom, Ian Yates
Filed: 18 Sep 20
Utility
[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL Substituted Indole Compounds
17 Aug 23
Alaric J. DYCKMAN, Dharmpal S. Dodd, Tasir Shamsul Haque, Louis J. Lombardo, John E. Macor, Christopher P. Mussari, Laxman Pasunoori, Sreekantha Ratna Kumar, Trevor C. Sherwood, Shoshana L. Posy, Ramesh Kumar Sistla, Subramanya Hegde, Anupama Kandhi Ramachandra Reddy
Filed: 26 Apr 23
Utility
Methods of Treating Acute Respiratory Disorders
17 Aug 23
The present disclosure provides methods of treating, stabilizing, or lessening the severity or progression of an acute respiratory disorder.
Alan F. Corin, John Michael Ellis, Francisco Ramirez-Valle, Kofi Agyare Mensah
Filed: 22 Jul 21
Utility
Process for Synthesizing Lipids
10 Aug 23
Gregory Louis Beutner, Federico Lora Gonzalez, Patricia Y. Cho, Michael J. Smith
Filed: 22 Jun 21
Utility
Pyrazolone Formyl Peptide 2 Receptor Agonists
10 Aug 23
James A. Johnson, Zulan Pi, Nicholas R. Wurtz, Joanne M. Smallheer, Meriah Neissel Valente, Ellen K. Kick, Charles G. Clark, Pravin Sudhaka Shirude, Balaji Kumar Seshadri, Amit Kumar Chattopadhyay
Filed: 8 Jul 21
Utility
Methods to Manipulate Quality Attributes of Polypeptides Produced In Cho Cells
10 Aug 23
In accordance with the present invention, CHO cells expressing a recombinant polypeptide of interest are grown in media where the amino acids, vitamins, phosphate, lipids and/or antioxidant optimization is utilized to manipulate and/or control the protein quality attributes of the polypeptides.
Jun Tian
Filed: 18 Apr 23
Utility
Process for Synthesizing Targeting Molecules
10 Aug 23
Zhongping Shi, Yichen Tan, Federico Lora Gonzalez, Ronald Carrasquillo-Flores, Michael J. Smith
Filed: 22 Jun 21
Utility
Methods of Treating Prostate Cancer
3 Aug 23
The present application relates generally to methods for treating prostate cancer with a lysine specific demethylase-1 (LSD-1) inhibitor, wherein the lysine specific demethylase-1 (LSD-1) inhibitor resensitizes the prostate cancer cells to androgen receptor pathway inhibitor (ARPI) treatment.
JUAN DE ALVARO, JOSEP LLUIS PARRA-PALAU, ZARIANA NIKOLOVA, JORGE DI MARTINO, ELLEN FILVAROFF, IDA ARONCHIK, MARTINA MALATESTA
Filed: 4 Jun 21
Utility
Imaging Methods Using 18F-RADIOLABELED Biologics
3 Aug 23
The invention relates to water soluble 18F-prosthetic groups and the synthesis and use of 18F-labeled biological molecules containing the 18F-prosthetic groups for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.
David DONNELLY, David K. LEUNG
Filed: 10 Nov 22